PRKAA2 and neoplasm: In multiple myeloma xenograft mice models, MTF treatment (250 mg/kg daily) substantially sustained the in vitro findings by reducing tumor size, increasing expression of p-AMPK, and decreasing expression of p-mTOR and Ki67.